You are here

aficamten

Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision

Fierce Biotech

Fri, 12/20/24 - 11:26 am

Corxel Pharmaceuticals

FDA kicks off review of Cytokinetics' aficamten for HCM

Pharmaphorum

Tue, 12/3/24 - 09:39 am

obstructive hypertrophic cardiomyopathy

Bristol Myers Squibb

Bayer lands regional rights to aficamten in Japan deal with Cytokinetics

First Word Pharma

Tue, 11/19/24 - 11:20 am

hypertrophic cardiomyopathy

Eyeing drug launch in 2025, Cytokinetics rolls out HCM awareness campaign

Medical Marketing and Media

Sun, 11/10/24 - 09:30 pm

hypertrophic cardiomyopathy

Investors say 'no bueno' as Cytokinetics stymies M&A prospects with complex Royalty deal

Fierce Biotech

Thu, 05/23/24 - 11:04 am

Cytokinetics shows hand in high stakes rivalry with BMS' Camzyos

Fierce Biotech

Mon, 05/13/24 - 11:08 am

Bristol Myers Squibb

Novartis in advanced talks to buy Cytokinetics

Reuters

Mon, 01/8/24 - 10:29 pm

Cytokinetics' heart failure drug improves exercise capacity, sending shares soaring in long-awaited win

Fierce Biotech

Wed, 12/27/23 - 11:06 pm

Cytokinetics initiates trial of aficamten to treat nHCM

Clinical Trials Arena

Thu, 09/7/23 - 10:47 am

clinical trials

non-obstructive hypertrophic cardiomyopathy

As Cytokinetics’s ALS drug fails Phase III, focus turns to cardiomyopathy candidate

Clinical Trials Arena

Mon, 04/24/23 - 11:23 am

clinical trials